吉西他滨联合氟脲嘧啶脱氧核苷治疗晚期原发性肝癌临床研究  

Clinical study on gemcitabine combined with floxuridine in the treatment of advanced primary liver carcinoma

作　　者：任中海[1] 张成辉[1] 李长生[1] 薛永飞[1] 李明[1] 张敬伟[1] 

机构地区：[1]河南省南阳市中心医院肿瘤科,河南南阳473000

出　　处：《世界肿瘤杂志》2007年第4期272-273,共2页Tumour Journal of the World

摘　　要：目的观察吉西他滨（GEM）联合氟脲嘧啶脱氧核苷（FUDR）的FG方案治疗晚期肝癌的临床效果与不良反应。方法采用吉西他滨（GEM）联合氟脲嘧啶脱氧核苷（FUDR）治疗37例晚期原发性肝癌病人。GEM1000mg／m^2，静脉滴注，30min，dl、d8；FUDR1000mg／m^2，持续静脉滴注，d1、d4；21d为一个周期。所有病例均至少完成2周期治疗后评价疗效。结果37例中CR（完全缓解）1例，PR（部分缓解）9例，MR（好转）13例，SD（稳定）8例，PD（进展）6例。RR率27．0％，临床受益率（CR＋PR＋MR＋SD）为83．8％。中位生存时间为10．2mo，1a生存率43．2％。骨髓抑制以白细胞减少为主，发生率32．4％。黏膜炎和腹泻的发生率增加，但均为Ⅰ～Ⅱ度，发生率分别为21．6％和29．7％。结论FG方案明显延长了病人的生存时间并提高了生活质量。值得临床进一步研究。Objective To evaluate the clinical efficacy and toxicity of gemcitabine combined with floxuridine in the treatment of advanced primary liver carcinoma. Methods 37 patients with advanced primary liver carcinoma were treated with FG regime（gemcitabine 1000mg/m^2, ivgtt, 30min, d1＋8; and floxuridine 1000mg/m^2 civ, dl, d4）. Twenty-one days were considered as one cycle. The efficacy of patients was evaluated after at least two cycles. Results The total response rate of the 37 patients enrolled in this study was 27.0%. CR was one, PR was 9, MR was 13, SD was 8 and PD was 6. The clinical profit rate （CR＋PR＋MR＋SD） was 83.8%. The mean survival time for all 37 patients was 10.2 month and the 1-year survival rate was 43.2%. Myelosuppression was characteristic of leucocytopenia and the incidence rate was 32.4%. The incidence rates of membranitis and diarrhea were 21.6% and 29.7%. Conclusions The FG regime can obviously improve life quality with survival time prolong.

关 键 词：原发性肝癌 吉西他滨 氟脲嘧啶脱氧核苷 化学治疗 

分 类 号：R735.7[医药卫生—肿瘤] R730.53[医药卫生—临床医学]